Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ME2 | P23368 | 11/20 | 0.61 |
| ▸ | ME1 | P48163 | 11/20 | 0.61 |
| ▸ | ME3 | Q16798 | 11/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CHIA | Q9BZP6 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
| ▸ | CASP7 | P55210 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | CRHBP | P24387 | 1/20 | 0.46 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29575967 | 1.00 | ME2 (0.61) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL29576816 | 0.86 | MAPT (0.54) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL29576808 | 0.86 | ME2 (0.53) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL23244389 | 0.86 | ME2 (0.53) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL23245139 | 0.86 | MAPT (0.54) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL23244284 | 0.85 | ME2 (0.53) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL29576190 | 0.85 | ME2 (0.53) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL23244233 | 0.79 | ME2 (0.64) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL29576118 | 0.79 | ME2 (0.64) | ME2ME1ME3MAPTKMT2A | |
| SCHEMBL23244100 | 0.77 | ME2 (1.00) | ME2ME1ME3KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | claimed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | claimed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | claimed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| US-11225480-B2 | Malic enzyme inhibitors | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2022-01-18 | — | — | US | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021074898-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2021-04-22 | — | — | WO | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | SUN PHARMA ADVANCED RESEARCH COMPANY LTD (IN) | 2021-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115038-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | ME2 2/4885ME1 1/4885ME3 3/4885 |
| US-11225480-B2 | Malic enzyme inhibitors | ME1, RNASE1, ME2 | ME2 3/4885ME1 1/4885ME3 4/4885 |
| US-20220127266-A1 | MALIC ENZYME INHIBITORS | ME1, ME2, ME3 | ME2 2/4885ME1 1/4885ME3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.